ELP1 rs75834898: Understanding Carrier Status
The rs75834898 variant, also known as c.2204+6T>C, is a well-documented genetic change in the ELP1 gene. It is primarily recognized as a founder mutation associated with carrier status for familial dysautonomia, an autosomal recessive condition.
What each genotype means
Typical ELP1 genotype
This genotype represents the common, functional version of the ELP1 gene. Individuals with this result do not carry the specific splice-donor mutation associated with familial dysautonomia (Riley-Day syndrome).
This is the most common genotype in all populations, including those of Ashkenazi Jewish descent.
Familial dysautonomia carrier
This genotype indicates you are a carrier of the c.2204+6T>C mutation in the ELP1 gene, which is the primary cause of familial dysautonomia when inherited in two copies. As a carrier, you are typically asymptomatic, but you may wish to consult with a genetic counselor regarding reproductive risks if you are of Ashkenazi Jewish ancestry.
This genotype is found in approximately 1 in 30 individuals of Ashkenazi Jewish descent.
Familial dysautonomia risk
This genotype indicates the presence of two copies of the c.2204+6T>C mutation, which is the major cause of familial dysautonomia. This condition is a recessive sensory and autonomic neuropathy that typically presents at birth; please consult with a medical professional or clinical geneticist for diagnostic confirmation and clinical evaluation.
This genotype is rare and is almost exclusively observed in individuals of Ashkenazi Jewish descent.
What is the rs75834898 Variant?
The variant rs75834898, frequently referred to in scientific literature as IVS20+6T>C, is a specific change in the DNA sequence of the ELP1 gene (formerly known as IKBKAP). Located at the donor splice site of intron 20, this variant involves a single nucleotide substitution where a thymine (T) is replaced by a cytosine (C). This specific location is critical because it acts as a signal for the cellular machinery to correctly process messenger RNA (mRNA). When this signal is altered, the cell may incorrectly skip exon 20 during the splicing process. This error leads to the production of an unstable or truncated version of the ELP1 protein, particularly in nervous system tissues. Because this variant is a classic example of a splice-site mutation, it has been extensively studied to understand how small changes in non-coding regions can have significant impacts on protein function and human health.
The Role of the ELP1 Gene
The ELP1 gene provides the instructions for creating the Elongator complex protein 1. This protein is a vital component of the Elongator complex, which plays a multifaceted role in cellular processes, including the regulation of gene expression and the modification of transfer RNA (tRNA). In the human body, the ELP1 protein is expressed in various tissues, but it is particularly essential for the development and survival of neurons in the peripheral nervous system. These neurons are responsible for sensory functions and the autonomic nervous system, which controls involuntary bodily functions like heart rate, blood pressure, and temperature regulation. When the ELP1 protein is absent or significantly reduced due to genetic mutations, these critical neural pathways fail to develop or function correctly, leading to the clinical features observed in conditions like familial dysautonomia.
Research and Clinical Associations
Research has firmly established that the rs75834898 variant is the primary cause of familial dysautonomia (also known as Riley-Day syndrome) when inherited in an autosomal recessive pattern. This means an individual must inherit two copies of the pathogenic variant—one from each parent—to manifest the condition. The evidence for this association is strong, with studies consistently showing that over 99% of individuals of Ashkenazi Jewish descent with familial dysautonomia carry this specific mutation. While the variant is classified as pathogenic, it is important to note that being a carrier (having only one copy) does not typically result in the symptoms of the disease. Clinical testing for this variant is standard in reproductive genetic screening for populations with higher carrier frequencies. As with all genetic findings, individuals concerned about their carrier status or family history should consult with a genetic counselor or a qualified healthcare provider to discuss the implications of their results.
Population Frequency
The rs75834898 variant is notably more common in individuals of Ashkenazi Jewish ancestry compared to the general global population. Scientific studies have estimated the carrier frequency within this specific ethnic group to be approximately 1 in 32, or roughly 3%. This high frequency is attributed to a founder effect, where the mutation was introduced and maintained within a smaller, historically isolated population. Outside of the Ashkenazi Jewish population, the variant is extremely rare. Because of this distinct distribution, genetic screening programs often prioritize testing for this variant in individuals of Ashkenazi Jewish descent who are planning a family. Understanding these population-specific frequencies is a key component of modern clinical genetics, helping to provide context for why certain genetic conditions appear more frequently in specific ancestral groups.
What This Information Means for You
If you have received information regarding your status for the rs75834898 variant, it is important to understand that this is a carrier status result. Being a carrier means you have one copy of the variant and one typical copy of the gene; carriers are generally asymptomatic. However, if both parents are carriers, there is a 25% chance for each child to inherit two copies of the variant, which would result in the child having familial dysautonomia. This information is most relevant for family planning and reproductive health. You cannot change your genetic sequence, but you can use this knowledge to make informed decisions. If you are concerned about your results or your family's health history, the most appropriate step is to speak with a board-certified genetic counselor. They can provide personalized guidance, explain the risks, and help you navigate the complexities of genetic testing and inheritance patterns.
How common is this variant?
The rs75834898 variant has a carrier frequency of approximately 1 in 32 (3.2%) in the Ashkenazi Jewish population, while it is extremely rare in other global populations.
Frequently asked questions
What is familial dysautonomia?
Familial dysautonomia is a rare, inherited disorder that affects the development and survival of sensory and autonomic neurons. It leads to difficulties with involuntary body functions such as blood pressure control, temperature regulation, and digestion.
Does being a carrier mean I have the disease?
No, being a carrier means you have one copy of the variant and one typical copy of the gene. Carriers do not typically show symptoms of the disease, but they can pass the variant to their children.
Should I get tested for this variant?
Genetic testing for this variant is often recommended for individuals of Ashkenazi Jewish descent who are planning a family. You should discuss the necessity and implications of this testing with a healthcare provider or genetic counselor.
Is there a cure for familial dysautonomia?
There is currently no cure for familial dysautonomia. Treatment focuses on managing the symptoms and providing supportive care to improve the quality of life for affected individuals.
Sources & further reading
Educational information only, last refreshed 9/24/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs75834898?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in IKBKAP
Major founder splicing mutation (c.2204+6T>C) in ELP1 (IKBKAP) causing familial dysautonomia.
Founder splice-site mutation in ELP1/IKBKAP (c.2204+6T>C) conferring carrier status for familial dysautonomia (Riley-Day syndrome).
This variant is a primary mutation accounting for the majority of familial dysautonomia cases in Ashkenazi Jewish populations.